NASDAQ:IMNM

Immunome Stock Insider Trading

Healthcare > Biotechnology

Buy IMNM

*Your capital is at risk

$22.76

-0.320 (-1.39%)

At Close: Jul 31, 2026

Immunome Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.39. In total, the insiders bought 6.23M and sold 1.21M IMNM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.39
● Buy	6.23M shares
● Sell	1.21M shares
74% Buy Activity Strong Negative Correlation
Buy Signal Low Confidence Jul 23, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -36.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 23, 2026 Buy	Common Stock A-Award	Siegall Clay B President And CEO	CEO / President	180 000 Value: $3.96M
Jul 23, 2026 Buy	Common Stock A-Award	Lechleider Robert Chief Medical Officer	Officer	54 000 Value: $1.19M
Jul 23, 2026 Buy	Common Stock A-Award	Rosett Max Chief Financial Officer	C-Suite Officer	47 250 Value: $1.04M
Jul 23, 2026 Buy	Common Stock A-Award	Higgins Jack Chief Scientific Officer	Officer	38 250 Value: $841.9K
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Stoneman Sandra G. Chief Legal Officer & GC	Officer	76 500 Value: $1.68M
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Tsai Philip Chief Technical Officer	Officer	76 500 Value: $1.68M
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Horn Kinney Chief Business Officer	Officer	62 500 Value: $1.38M
Jul 23, 2026 Buy	Common Stock A-Award	Horn Kinney Chief Business Officer	Officer	31 250 Value: $687.8K
Jul 23, 2026 Buy	Common Stock A-Award	Tsai Philip Chief Technical Officer	Officer	38 250 Value: $841.9K
Jul 23, 2026 Buy	Common Stock A-Award	Stoneman Sandra G. Chief Legal Officer & GC	Officer	38 250 Value: $841.9K
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Higgins Jack Chief Scientific Officer	Officer	76 500 Value: $1.68M
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Rosett Max Chief Financial Officer	C-Suite Officer	94 500 Value: $2.08M
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Lechleider Robert Chief Medical Officer	Officer	108 000 Value: $2.38M
Jul 23, 2026 Buy	Employee Stock Option (right to buy) A-Award	Siegall Clay B President And CEO	CEO / President	360 000 Value: $7.92M
Jul 07, 2026 Buy	Common Stock M-Exempt	Horn Kinney Chief Business Officer	Officer	1 092 Value: $14.1K
Jul 07, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Horn Kinney Chief Business Officer	Officer	1 092 Value: $14.1K
Jul 07, 2026 Sell	Common Stock S-Sale	Horn Kinney Chief Business Officer	Officer	1 092 Value: $27.3K
Jul 07, 2026 Sell	Common Stock S-Sale	Barchas Isaac Director	Director	16 906 Value: $409.1K
Jul 06, 2026 Sell	Common Stock S-Sale	Barchas Isaac Director	Director	83 094 Value: $2.00M
Jul 02, 2026 Sell	Common Stock S-Sale	Lechleider Robert Chief Medical Officer	Officer	16 072 Value: $376.7K
Jul 02, 2026 Sell	Common Stock S-Sale	Lechleider Robert Chief Medical Officer	Officer	16 214 Value: $369.0K
Jul 02, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Lechleider Robert Chief Medical Officer	Officer	55 000 Value: $480.2K
Jul 02, 2026 Buy	Common Stock M-Exempt	Lechleider Robert Chief Medical Officer	Officer	55 000 Value: $480.2K
Jul 02, 2026 Sell	Common Stock S-Sale	Lechleider Robert Chief Medical Officer	Officer	22 714 Value: $498.6K
Jul 02, 2026 Sell	Common Stock S-Sale	Barchas Isaac Director	Director	24 335 Value: $567.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNOME, INC.

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...

Read Full Profile Here